Mifamurtide (Mepact)
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First approval | EU centralised authorisation 6 Mar 2009 (holder now Esteve Pharmaceuticals S.A.), about 17 years | EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026) |
| Mechanism | Synthetic version of part of a bacterial cell wall, in fat bubbles (liposomes); activates monocytes and macrophages (white blood cells) | EMA EPAR https://www.ema.europa.eu/en/medicines/human/EPAR/mepact (via entries.json) |
| Use in osteosarcoma | Ages 2 to 30, high-grade, non-metastatic, after complete surgical removal, with chemotherapy; twice a week for 12 weeks then weekly for 24 weeks (48 infusions over 36 weeks), each a one-hour infusion | EMA EPAR https://www.ema.europa.eu/en/medicines/human/EPAR/mepact (accessed 4 Nov 2026) |
| Combined with | Post-operative chemotherapy (in INT-0133, MAP with or without ifosfamide) | doi:10.1200/JCO.2008.14.0095 (accessed 3 Nov 2026) |
| Results | INT-0133, 678 patients: 6-year overall survival 70% to 78% (P=.03); event-free survival 61% to 68% (entries.json) | doi:10.1200/JCO.2008.14.0095 (PMID 18235123) |
| Side effects | More than 1 in 10 include fever, chills, tiredness, headache, dizziness, nausea, vomiting, fast heartbeat, high or low blood pressure, breathlessness, muscle pain, anaemia | EMA EPAR Mepact (accessed 4 Nov 2026) |
| Owner | IDM Pharma held the EU authorisation in 2009; Takeda completed acquisition of IDM on 24 Jun 2009; EU holder now Esteve Pharmaceuticals S.A. Not generic | Takeda release via SEC, https://www.sec.gov/Archives/edgar/data/822206/000110465909040297/a09-16803_2ex99d2.htm (accessed 4 Nov 2026); EMA EPAR (accessed 4 Nov 2026) |
| Regulatory | EU: authorised 2009. UK: PL 08498/0043; NICE TA235 recommends ages 2 to 30. US: FDA not-approvable letter 2007, orphan designation 2001 only. China: no approval record found | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026; FDA https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=143401; Level 2 facts table (4 Nov 2026) |
| Trials now | SARCOME13 (France, high-risk), MEMOS (UK, advanced), Dragonfly v sorafenib (NCT07787429) | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
| Debate | ESMO 2021: no consensus on use; not reimbursed in all European countries | doi:10.1016/j.annonc.2021.08.1995 (via treatment_by_country.md) |
Hypotheses and open points (not established fact)
- Benefit in metastatic or poor-response disease: under test (SARCOME13, MEMOS); unknown.
- The FDA judged the INT-0133 design (factorial, interaction with ifosfamide) insufficient; interpretation debated.